Should I buy or sell Werewolf Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Werewolf Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" HOWL shares. View HOWL analyst ratings or view top-rated stocks .

What is Werewolf Therapeutics' stock price target for 2024?

3 brokerages have issued 1-year price targets for Werewolf Therapeutics' stock. Their HOWL share price targets range from $8.30 to $15.00. On average, they anticipate the company's share price to reach $10.58 in the next year. This suggests a possible upside of 264.7% from the stock's current price. View analysts price targets for HOWL or view top-rated stocks among Wall Street analysts .

How have HOWL shares performed in 2023?

Werewolf Therapeutics' stock was trading at $2.05 at the start of the year. Since then, HOWL shares have increased by 41.5% and is now trading at $2.90. View the best growth stocks for 2023 here .

Are investors shorting Werewolf Therapeutics?

Werewolf Therapeutics saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 518,500 shares, an increase of 62.8% from the October 31st total of 318,400 shares. Based on an average daily volume of 827,000 shares, the days-to-cover ratio is presently 0.6 days. Currently, 2.3% of the shares of the company are short sold. View Werewolf Therapeutics' Short Interest .

When is Werewolf Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024. View our HOWL earnings forecast .

How were Werewolf Therapeutics' earnings last quarter?

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) issued its quarterly earnings results on Tuesday, November, 14th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.04. The firm had revenue of $5.90 million for the quarter, compared to analyst estimates of $15.60 million. Werewolf Therapeutics had a negative net margin of 144.98% and a negative trailing twelve-month return on equity of 31.44%.

When did Werewolf Therapeutics IPO?

(HOWL) raised $101 million in an IPO on Friday, April 30th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, SVB Leerink and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.

Who are Werewolf Therapeutics' major shareholders?

Werewolf Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Schonfeld Strategic Advisors LLC (0.49%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bioventures 2014 LP Mpm, Ra Capital Management, LP and Reid Leonard . View institutional ownership trends .

How do I buy shares of Werewolf Therapeutics?

Shares of HOWL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Werewolf Therapeutics Stock Price, News & Analysis (NASDAQ:HOWL)

$2.90

-0.02 (-0.68%)

(As of 12/8/2023 ET)

Compare

Today's Range: $2.85
▼
$2.96
50-Day Range: $1.78
▼
$3.17
52-Week Range: $1.55
▼
$4.57

Volume: 33,597 shs
Average Volume: 138,213 shs
Market Capitalization: $104.95 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.58

Werewolf Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 264.7% Upside
$10.58 Price Target
Short Interest: Healthy
2.30% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.05
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.03) to ($1.30) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.32 out of 5 stars

Medical Sector

238th out of 954 stocks

Pharmaceutical Preparations Industry

60th out of 362 stocks

3.5

Analyst's Opinion

Consensus Rating
Werewolf Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.58, Werewolf Therapeutics has a forecasted upside of 264.7% from its current price of $2.90.
Amount of Analyst Coverage
Werewolf Therapeutics has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.30% of the float of Werewolf Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Werewolf Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Werewolf Therapeutics has recently increased by 62.85%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Werewolf Therapeutics does not currently pay a dividend.
Dividend Growth
Werewolf Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for HOWL.

2.8

News and Social Media Coverage

News Sentiment
Werewolf Therapeutics has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Werewolf Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for HOWL on MarketBeat in the last 30 days. This is a decrease of -88% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Werewolf Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Werewolf Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
26.10% of the stock of Werewolf Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
67.44% of the stock of Werewolf Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Werewolf Therapeutics are expected to decrease in the coming year, from ($1.03) to ($1.30) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Werewolf Therapeutics is -2.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Werewolf Therapeutics is -2.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Werewolf Therapeutics has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Werewolf Therapeutics Stock (NASDAQ:HOWL)

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an IL-21 INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

HOWL Stock Price History

30 days | 90 days | 365 days | Advanced Chart

HOWL Stock News Headlines

December 7, 2023 | finance.yahoo.com

Institutions profited after Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) market cap rose US$14m last week but private equity firms profited the most

December 4, 2023 | realmoney.thestreet.com

Wolfspeed Could Rally in the Next Few Weeks: Should You Join the Pack?

December 9, 2023 | Autonomix (Ad)

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology

Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 22, 2023 | finance.yahoo.com

Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference

November 17, 2023 | msn.com

Folklore strategy game Howl is a turn-based puzzle for perfectionists

November 14, 2023 | finance.yahoo.com

Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

November 3, 2023 | msn.com

Why Is Werewolf Therapeutics (HOWL) Stock Up 20% Today?

November 3, 2023 | marketwatch.com

Werewolf Therapeutics Shares Jump on Encouraging Trial Data

December 9, 2023 | Autonomix (Ad)

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology

November 3, 2023 | benzinga.com

Werewolf Therapeutics' Cancer Drug Shows Promise in Early Study for Solid Tumors, Stock Soars

November 3, 2023 | msn.com

Werewolf Therapeutics jumps on early-sage data from lead program

November 3, 2023 | finance.yahoo.com

Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

November 1, 2023 | markets.businessinsider.com

Promising Phase 1 Results and Improved Therapeutic Index Drive ‘Buy’ Rating for Werewolf Therapeutics

November 1, 2023 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Werewolf Therapeutics (HOWL), Ascendis Pharma (ASND)

October 31, 2023 | finance.yahoo.com

Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

September 30, 2023 | finance.yahoo.com

This Just In: Analysts Are Boosting Their Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Outlook for This Year

September 28, 2023 | yahoo.com

The Best Werewolf Movies of All Time, from ‘Ginger Snaps’ to ‘Teen Wolf’ to ‘An American Werewolf in London’

September 27, 2023 | finance.yahoo.com

Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

September 14, 2023 | msn.com

'Lazy' Wolfdog Pretending to Howl for the Camera Has Internet in Stitches

September 11, 2023 | finance.yahoo.com

Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124

September 5, 2023 | finance.yahoo.com

Werewolf Therapeutics to Participate in Upcoming Investor Conferences

August 25, 2023 | msn.com

Wedbush Initiates Coverage of Werewolf Therapeutics (HOWL) with Outperform Recommendation

August 24, 2023 | msn.com

Werewolf gains as Wedbush cites bullish views ahead of key readout

August 24, 2023 | theglobeandmail.com

Biotech Soars On New Price Target And Analyst Rating

August 24, 2023 | markets.businessinsider.com

Small Cancer Player Werewolf Therapeutics' Stock Undervalued: Analyst Says Treatment Platform Underappreciated

August 13, 2023 | finance.yahoo.com

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

August 11, 2023 | finance.yahoo.com

Werewolf Therapeutics Second Quarter 2023 Earnings: Beats Expectations

See More Headlines

Receive HOWL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Werewolf Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/14/2023
Today: 12/09/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/28/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:HOWL
CUSIP: N/A
CIK: 1785530
Web: werewolftx.com
Phone: 617-952-0555
Fax: N/A
Employees: 46
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $10.58
High Stock Price Target: $15.00
Low Stock Price Target: $8.30
Potential Upside/Downside: +264.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.10)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-53,810,000.00
Net Margins: -144.98%
Pretax Margin: -144.98%
Return on Equity: -31.44%
Return on Assets: -20.81%

Debt

Debt-to-Equity Ratio: 0.33
Current Ratio: 9.64
Quick Ratio: 9.64

Sales & Book Value

Annual Sales: $25.73 million
Price / Sales: 4.08
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.98 per share
Price / Book: 0.73

Miscellaneous

Outstanding Shares: 36,192,000
Free Float: 26,746,000
Market Cap: $104.96 million
Optionable: Not Optionable
Beta: 0.18

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Dr. Daniel J. Hicklin Ph.D. (Age 59)
Founder, CEO, President, Secretary & Director
Comp: $817.31k
Dr. Cynthia Seidel-Dugan Ph.D. (Age 64)
Chief Scientific Officer
Comp: $600.35k
Dr. Randi Isaacs M.D. (Age 67)
Chief Medical Officer
Comp: $637.15k
Mr. Timothy W. Trost CPA (Age 65)
CFO, Treasurer & Assistant Secretary
Comp: $511.88k
Dr. Chulani Karunatilake Ph.D. (Age 64)
Chief Technology Officer
Comp: $343.43k
Ms. Ellen A. Lubman M.B.A. (Age 47)
Chief Business Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

HOWL Stock Analysis - Frequently Asked Questions

Should I buy or sell Werewolf Therapeutics stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Werewolf Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" HOWL shares.
View HOWL analyst ratings or view top-rated stocks.
What is Werewolf Therapeutics' stock price target for 2024?: 3 brokerages have issued 1-year price targets for Werewolf Therapeutics' stock. Their HOWL share price targets range from $8.30 to $15.00. On average, they anticipate the company's share price to reach $10.58 in the next year. This suggests a possible upside of 264.7% from the stock's current price.
View analysts price targets for HOWL or view top-rated stocks among Wall Street analysts.
How have HOWL shares performed in 2023?: Werewolf Therapeutics' stock was trading at $2.05 at the start of the year. Since then, HOWL shares have increased by 41.5% and is now trading at $2.90.
View the best growth stocks for 2023 here.
Are investors shorting Werewolf Therapeutics?: Werewolf Therapeutics saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 518,500 shares, an increase of 62.8% from the October 31st total of 318,400 shares. Based on an average daily volume of 827,000 shares, the days-to-cover ratio is presently 0.6 days. Currently, 2.3% of the shares of the company are short sold.
View Werewolf Therapeutics' Short Interest.
When is Werewolf Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our HOWL earnings forecast.

How were Werewolf Therapeutics' earnings last quarter?: Werewolf Therapeutics, Inc. (NASDAQ:HOWL) issued its quarterly earnings results on Tuesday, November, 14th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.04. The firm had revenue of $5.90 million for the quarter, compared to analyst estimates of $15.60 million. Werewolf Therapeutics had a negative net margin of 144.98% and a negative trailing twelve-month return on equity of 31.44%.
When did Werewolf Therapeutics IPO?: (HOWL) raised $101 million in an IPO on Friday, April 30th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, SVB Leerink and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.
Who are Werewolf Therapeutics' major shareholders?: Werewolf Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Schonfeld Strategic Advisors LLC (0.49%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bioventures 2014 LP Mpm, Ra Capital Management, LP and Reid Leonard.
View institutional ownership trends.
How do I buy shares of Werewolf Therapeutics?: Shares of HOWL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:HOWL) was last updated on 12/9/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial